Shares of Bayer AG (FRA:BAYN) have been assigned an average rating of “Hold” from the twenty brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is €80.47 ($93.57).
A number of equities research analysts have weighed in on the company. Nord/LB set a €64.00 ($74.42) target price on Bayer and gave the company a “neutral” rating in a report on Wednesday, October 30th. Goldman Sachs Group set a €77.00 ($89.53) target price on Bayer and gave the company a “buy” rating in a report on Monday. JPMorgan Chase & Co. set a €69.00 ($80.23) target price on Bayer and gave the company a “neutral” rating in a report on Monday. Warburg Research set a €61.00 ($70.93) target price on Bayer and gave the company a “neutral” rating in a report on Monday, October 7th. Finally, Morgan Stanley set a €86.00 ($100.00) target price on Bayer and gave the company a “buy” rating in a report on Tuesday, November 12th.
Shares of BAYN stock traded up €0.03 ($0.03) during trading hours on Friday, reaching €68.53 ($79.69). The company’s stock had a trading volume of 2,428,406 shares. The firm’s 50 day simple moving average is €67.21 and its 200-day simple moving average is €61.86. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Why do companies issue monthly dividends?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.